We read with interest the report by Ponce de Leon et al,¹ where the authors argued that tuberculin skin testing (TST) may not be an optimal test for the diagnosis of latent tuberculosis infection (LTBI) in patients with rheumatoid arthritis. We would like to contribute to these findings, based on our clinical experience with a new screening tool called the QuantiFERON TB-Gold (QFT-G) Test.

Although screening policies vary considerably between countries, it is generally recommended that all patients with rheumatoid arthritis should undergo screening for Mycobacterium tuberculosis latent infection before the initiation of treatment with biological agents, especially tumour necrosis factor (TNF)α inhibitors.^{2 …}